April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
The Role of Rucaparib in Ovarian Cancer Following the ARIEL4 Readout
October 22nd 2022In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.
Read More
Hamilton Discusses the Role of PARP Inhibition in Advanced Ovarian Cancer
October 18th 2022During a Targeted Oncology case-based roundtable event, Chad Hamilton, MD, broke down the data that shows how the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer is impacting patients.
Read More
The Role of Biomarker Testing in Ovarian Cancer
October 17th 2022There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.
Read More
Phase 1b Expansion Study of PY159 Doses First Patient With Ovarian Cancer
September 21st 2022Enrollment has begun in the phase 1b trial examining PY159 alone and in combination with pembrolizumab in patients with unresectable and/or metastatic solid tumors that are refractory or relapsed to standard of care.
Read More
sNDA Submitted to the FDA for Rucaparib in Advanced Ovarian Cancer
September 13th 2022Data from the monotherapy analysis of the phase 3 ATHENA trial has led to the submission of a supplemental new drug application to the FDA and EMA for rucaparib as treatment for patients with advanced ovarian cancer.
Read More
Benefit of Maintenance Rucaparib in Ovarian Cancer Seen Across Subgroups
September 11th 2022Maintenance rucaparib (Rubraca) induced a progression-free survival (PFS) improvement in patients with newly diagnosed ovarian cancer compared with placebo, which was also seen across all prespecified subgroups.
Read More
DS-6000a Displays Early Clinical Activity in Ovarian Cancer and RCC
August 24th 2022In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.
Read More
Powell Reviews Trials of PARP Inhibition in BRCA-Positive Ovarian Cancer
July 21st 2022During a Targeted Oncology case-based roundtable event, Matthew Powell, MD, discussed trials supporting the use of the PARP inhibitors niraparib and olaparib for patients with BRCA-positive ovarian cancer.
Read More
Frontline Bevacizumab Beneficial for Ovarian Clear Cell Carcinoma, Retrospective Analysis Shows
June 6th 2022Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.
Read More
First-line Niraparib Improves PFS in Ovarian Cancer
May 18th 2022An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,
Read More